Jianming Zhang

Years Active: 2021-2023
Publications (10 Years): 4

This page only lists publications with an associated author ORCID identifier.

Publications

Canlin Yang, Fei Li, Yuanyuan Ren, Qianqian Zhang, Bo Jiao, Jianming Zhang, Junxing Huang
Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4. Cancers 15 (22) (2023)
Xuhui Ma, Shanshan Wu, Botai Li, Qianqian Zhang, Jianming Zhang, Wenming Liu, He-Xin Yan, René Bernards, Wenxin Qin, Cun Wang
EGFR blockade confers sensitivity to cabozantinib in hepatocellular carcinoma. Cell discovery 8 (1) (2022)
Yongyun Li, Jie Yang, Qianqian Zhang, Shiqiong Xu, Wei Sun, Shengfang Ge, Xiaowei Xu, Martine J Jager, Renbing Jia, Jianming Zhang, Xianqun Fan
Copper ionophore elesclomol selectively targets GNAQ/11-mutant uveal melanoma. Oncogene 41 (27) (2022)
Yue Lu, Zhenzhen Fan, Su-Jie Zhu, Xiaoxing Huang, Zhongji Zhuang, Yunzhan Li, Zhou Deng, Lei Gao, Xuehui Hong, Ting Zhang, Li Li, Xihuan Sun, Wei Huang, Jingfang Zhang, Yan Liu, Baoding Zhang, Jie Jiang, Fu Gui, Zheng Wang, Qiyuan Li, Siyang Song, Xin Huang, Qiao Wu, Lanfen Chen, Dawang Zhou, Jianming Zhang, Cai-Hong Yun, Liang Chen, Xianming Deng
A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC. EMBO molecular medicine (2021)

Jianming Zhang.css-eqlu8i{font-size:small;padding-left:4px;}